Browsing Tag
UroGen Pharma Ltd.
3 posts
What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Discover what it means for NMIBC competition and growth.
Hope for bladder cancer patients? UroGen’s UGN-301 shows strong safety and clinical activity in early trial
Find out how UroGen Pharma’s UGN-301 is offering new hope for bladder cancer patients with promising Phase 1 trial results. Read the latest developments here!
Breakthrough for recurrent bladder cancer: UroGen’s UGN-102 achieves 80.6% 18-month complete response in phase 3 trial
Discover how UroGen Pharma’s UGN-102 could transform bladder cancer treatment with durable results; find out what the Phase 3 ENVISION trial reveals!